TP53 and colorectal carcinoma: Conversely, the mutant p53 variant pLNCX‐Flag‐p53‐R273H‐mTAD, rendering its transactivation region nonfunctional, did not increase the survival of CRC cells treated with cholesterol or siSQLE under anoikis resistance (Jun et al., 2021).